Xeureka Held the Third Executive Board Meeting of Tokyo-1

On December 16, 2025, the third Executive Board meeting of Tokyo-1 was held at Mitsui & Co. headquarters. Executives from Astellas Pharma, Ono Pharmaceutical, Daiichi Sankyo, and NVIDIA, all participating in Tokyo-1, joined the session to share the latest updates from their respective companies and engage in lively discussions.

In the first session, the Mitsui & Co. Global Strategic Studies Institute presented macro-level political and economic trends, focusing on the United States, while NVIDIA introduced advanced global case studies and industry trends in the field of AI-driven drug discovery. Xeureka reported on its initiatives over the past two years to strengthen its co-creation and collaboration-based community, and shared future expansion plans, including broadening community activities and realizing joint research projects—outlining the direction Tokyo-1 aims to pursue.

The second session took place in a networking format, featuring presentations from Mitsui Knowledge Industry on the current status and future outlook of the large-scale computing infrastructure supporting Tokyo-1, as well as from participating pharmaceutical companies on the achievements realized through their involvement in Tokyo-1. Midway through the event, interviews from the recent hackathon* were showcased, conveying the passion and enthusiasm of on-site members toward Tokyo-1.

Executives expressed strong expectations for the continued growth of Tokyo-1, particularly its active community initiatives, including collaborative validation in non-competitive domains.

Tokyo-1 will continue to accelerate innovation as a pioneering collective driving the utilization of AI in Japan’s drug discovery sector. Looking ahead, we aim to expand our network further and establish Tokyo-1 as the de facto standard for AI-driven drug discovery in Japan, nurturing it together as a world-class hub for pharmaceutical innovation.

*Tokyo-1 Drug Discovery Hackathon 2025 Event Report